DGIdb - ERBB3 Gene Record

ERBB3 2065 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

2065
ERB-B2 RECEPTOR TYROSINE KINASE 3
ERBB3
ErbB-3
HER3
LCCS2
MDA-BF-1
c-erbB-3
c-erbB3
erbB3-S
p180-ErbB3
p45-sErbB3
p85-sErbB3
190151
3431
ENSG00000065361
OTTHUMG00000170140
RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 PRECURSOR (EC 2.7.1.112) (C- ERBB3) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER3). [SOURCE:UNIPROT/SWISSPROT;ACC:P21860]
1733
P21860
Receptor tyrosine-protein kinase erbB-3
Proto-oncogene-like protein c-ErbB-3
Tyrosine kinase-type cell surface receptor HER3
ERBB3_HUMAN
EGFR (HER1/ERBB1)HER2 (ERBB2/neu)HER3 (ERBB3)
HER3 (ERBB3)
PA27846
Erbb3 tyrosine kinase receptor
T86350
FERLK
VSCN1

Gene Info:

Human Readable Name	DRUGGABLE GENOME
Uniprot Evidence	1: Evidence at protein level
Interpro Name	Serine-threonine/tyrosine-protein kinase catalytic domain
Interpro Type	Domain
Uniprot Status	Swiss-Prot
Interpro Short Name	Ser-Thr/Tyr_kinase_cat_dom
Human Readable Name	KINASE
Interpro Acc	IPR001245
Target Class	Receptors
Target Subclass	EC:2.7.10.1
Gene Biotype	PROTEIN_CODING

(20 More Sources)

Gene Categories: Category Details

KINASE
TYROSINE KINASE
DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE
ENZYME

Publications:

Jaiswal et al., 2013, Oncogenic ERBB3 mutations in human cancers., Cancer Cell
Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One
Bidard FC et al., 2015, Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer., Ann Oncol
Leary et al., 2015, Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)., Clin. Cancer Res.
Thomas et al., 2014, HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models., Oncotarget
Capparelli et al., 2015, ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas., Cancer Res.
Wada K et al., 2015, Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects., Bioorg Med Chem
Choudhury et al., 2016, Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations., J. Clin. Oncol.
Sun et al., 2014, Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3., Cell Rep
Cheng et al., 2015, Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma., Cancer Res.
Cushman et al., 2015, Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)., Clin. Cancer Res.

MM-121 ERBB3

Interaction Score: 8.24

Interaction Types & Directionality:

antibody (inhibitory)

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions TTD
AMG-888 ERBB3

Interaction Score: 4.12

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome
AV-203 ERBB3

Interaction Score: 4.12

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC TTD
MM-111 ERBB3

Interaction Score: 2.06

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Trial Name MM-111

Novel drug target Novel Target

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial
SAPITINIB ERBB3

Interaction Score: 2.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions
DULIGOTUZUMAB ERBB3

Interaction Score: 2.06

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
MyCancerGenome TTD
PATRITUMAB ERBB3

Interaction Score: 2.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 inhibitor

PMIDs:
None found

Sources:
ChemblInteractions TTD
PERTUZUMAB ERBB3

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status preclinical

PMIDs:
23680147 25216528 26206558

Sources:
DoCM CIViC
MARGETUXIMAB ERBB3

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial
DIMETHYLCURCUMIN ERBB3

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25753330

Sources:
DTC
ELGEMTUMAB ERBB3

Interaction Score: 1.03

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
METHYLCURCUMIN ERBB3

Interaction Score: 1.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25753330

Sources:
DTC
POZIOTINIB ERBB3

Interaction Score: 0.82

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial
DACOMITINIB ERBB3

Interaction Score: 0.82

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial
SERIBANTUMAB ERBB3

Interaction Score: 0.69

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
ISTIRATUMAB ERBB3

Interaction Score: 0.69

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD
AFATINIB ERBB3

Interaction Score: 0.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27044931 24685132

Sources:
CIViC
TRASTUZUMAB ERBB3

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status preclinical

PMIDs:
23680147 30071039 25953157

Sources:
DoCM CIViC PharmGKB
AC-480 ERBB3

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name AC480

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
OSIMERTINIB MESYLATE ERBB3

Interaction Score: 0.52

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LAPATINIB ERBB3

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

Clinical Status preclinical

Pathway activation

Variant Effect gain-of-function

PMIDs:
23680147 25398453 25953157

Sources:
DoCM CIViC PharmGKB
SELUMETINIB ERBB3

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24685132 25952648

Sources:
CIViC
GEFITINIB ERBB3

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
24685132

Sources:
CIViC MyCancerGenomeClinicalTrial PharmGKB
TRAMETINIB ERBB3

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25952648

Sources:
CIViC
CETUXIMAB ERBB3

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25520391

Sources:
CIViC
CURCUMIN ERBB3

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25753330

Sources:
DTC
DOCETAXEL ERBB3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30071039

Sources:
PharmGKB
CARBOPLATIN ERBB3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30071039

Sources:
PharmGKB
ERLOTINIB ERBB3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VANDETANIB ERBB3

Interaction Score: 0.04

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Ensembl: ENSG00000065361
- Version: 101_38
Alternate Names:

ERBB3 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
HopkinsGroom: P21860
- Version: 11-September-2012
Alternate Names:

P21860 Uniprot Accession

ERBB3 Uniprot Gene Name

ENSG00000065361 Ensembl Gene Id

Gene Info:

Uniprot Evidence 1: Evidence at protein level

Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain

Human Readable Name DRUGGABLE GENOME

Gene Categories:

KINASE, DRUGGABLE GENOME

Publications:

RussLampel: ENSG00000065361

Version: 26-July-2011

Alternate Names:

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 PRECURSOR (EC 2.7.1.112) (C- ERBB3) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER3). [SOURCE:UNIPROT/SWISSPROT;ACC:P21860] Description

ERBB3 Display Id

ENSG00000065361 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

TdgClinicalTrial: P21860
- Version: January-2014
Alternate Names:

ERBB3 Gene Symbol

Gene Info:

Target Class Receptors

Target Subclass EC:2.7.10.1

Publications:

PharmGKB: ERBB3

Version: 18-August-2020

Alternate Names:

PA27846 PharmGKB ID

Gene Info:

Publications:

Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One

CIViC: ERBB3

Version: 14-September-2020

Alternate Names:

2065 Entrez Gene ID

1733 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Sun et al., 2014, Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3., Cell Rep

Cheng et al., 2015, Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma., Cancer Res.

Choudhury et al., 2016, Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations., J. Clin. Oncol.

TTD: Erbb3 tyrosine kinase receptor
- Version: 2020.06.01
Alternate Names:

Erbb-3 TTD Gene Abbreviation

T86350 TTD Target ID

Gene Info:

Publications:

Dey N et al., 2015, A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK., Am J Transl Res
DoCM: ERBB3
- Version: 27-September-2017
Alternate Names:

Gene Info:

Publications:

Jaiswal et al., 2013, Oncogenic ERBB3 mutations in human cancers., Cancer Cell
DTC: ERBB3
- Version: 02-September-2020
Alternate Names:

Gene Info:

Publications:

Wada K et al., 2015, Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects., Bioorg Med Chem
ChemblInteractions: HER3
- Version: chembl_23
Alternate Names:

HER3 GENE_SYMBOL

ERBB3 GENE_SYMBOL

Receptor tyrosine-protein kinase erbB-3 UNIPROT

Gene Info:

Publications:
HingoraniCasas: ENSG00000065361
- Version: 31-May-2017
Alternate Names:

ENSG00000065361 Gene Symbol

ERBB3 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
MyCancerGenome: ERBB3
- Version: 20-Jun-2017
Alternate Names:

2065 Entrez Gene Id

ERBB3 MyCancerGenome Gene Symbol

HER3 (ERBB3) MyCancerGenome Reported Gene Name

Gene Info:

Publications:
TALC: HER3
- Version: 12-May-2016
Alternate Names:

HER3 Gene Symbol

Gene Info:

Publications:
HumanProteinAtlas: ERBB3
- Version: 19.3
Alternate Names:

ENSG00000065361 Ensembl Gene ID

HER3 Human Protein Atlas Gene Synonym

LCCS2 Human Protein Atlas Gene Synonym

Gene Info:

Gene Categories:

ENZYME

Publications:
GO: ERBB3
- Version: 01-February-2022
Alternate Names:

HER3 GO Gene Synonym

Gene Info:

Gene Categories:

TYROSINE KINASE

Publications:
Tempus: ERBB3
- Version: 11-November-2018
Alternate Names:

ERBB3 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: ERBB3
- Version: 27-Jun-2013
Alternate Names:

2065 Gene ID

ErbB-3 dGene Synonym

HER3 dGene Synonym

Gene Info:

Gene Categories:

KINASE, TYROSINE KINASE

Publications:
Pharos: ERBB3
- Version: 01-February-2022
Alternate Names:

Receptor tyrosine-protein kinase erbB-3 Gene Name

P21860 UniProt ID

Gene Info:

Gene Categories:

KINASE

Publications:
MyCancerGenomeClinicalTrial: ERBB3
- Version: 30-February-2014
Alternate Names:

Gene Info:

Publications:
MskImpact: ERBB3
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
ClearityFoundationClinicalTrial: ERBB3
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
FoundationOneGenes: ERBB3
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: ERBB3
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: ERBB3
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Mechanism of Interaction	Receptor tyrosine-protein kinase erbB-3 antagonist
Direct Interaction	yes

Variant Effect	gain-of-function
Pathway	activation
Clinical Status	preclinical

Mechanism of Interaction	Epidermal growth factor receptor inhibitor
Direct Interaction	yes

P21860	Uniprot Accession
ERBB3	Uniprot Gene Name
ENSG00000065361	Ensembl Gene Id

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 PRECURSOR (EC 2.7.1.112) (C- ERBB3) (TYROSINE KINASE-TYPE CELL SURFACE RECEPTOR HER3). [SOURCE:UNIPROT/SWISSPROT;ACC:P21860]	Description
ERBB3	Display Id
ENSG00000065361	Ensembl Gene Id

HER3	GENE_SYMBOL
ERBB3	GENE_SYMBOL
Receptor tyrosine-protein kinase erbB-3	UNIPROT

2065	Entrez Gene Id
ERBB3	MyCancerGenome Gene Symbol
HER3 (ERBB3)	MyCancerGenome Reported Gene Name

Receptor tyrosine-protein kinase erbB-3	Gene Name
P21860	UniProt ID

antibody (inhibitory)
antagonist (inhibitory)

ERBB3 Gene Record

ERBB3 2065 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: antibody (inhibitory) antagonist (inhibitory)

Interaction Info: Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 antagonist Direct Interaction yes

PMIDs: None found

Sources: MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC MyCancerGenome

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info: Notes

PMIDs: None found

Sources: TALC TTD

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info: Trial Name MM-111 Novel drug target Novel Target

PMIDs: None found

Sources: MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 inhibitor Direct Interaction yes Notes

PMIDs: None found

Sources: TALC MyCancerGenome ChemblInteractions

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info:

PMIDs: None found

Sources: MyCancerGenome TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 inhibitor

PMIDs: None found

Sources: ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info: Variant Effect gain-of-function Pathway activation Clinical Status preclinical

PMIDs: 23680147 25216528 26206558

Sources: DoCM CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25753330

Sources: DTC

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25753330

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Epidermal growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Epidermal growth factor receptor inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: antibody (inhibitory)

Interaction Info:

PMIDs: None found

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27044931 24685132

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Variant Effect gain-of-function Pathway activation Clinical Status preclinical

PMIDs: 23680147 30071039 25953157

Sources: DoCM CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Trial Name AC480 Novel drug target Novel Target

Interaction Types & Directionality:

antibody (inhibitory)

antagonist (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 antagonist

Direct Interaction yes

PMIDs:
None found

Sources:
MyCancerGenome ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC TTD

Interaction Types & Directionality:

antibody (inhibitory)

Interaction Info:

Trial Name MM-111

Novel drug target Novel Target

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome ChemblInteractions

Interaction Types & Directionality:

antibody (inhibitory)

PMIDs:
None found

Sources:
MyCancerGenome TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Receptor tyrosine-protein kinase erbB-3 inhibitor

PMIDs:
None found

Sources:
ChemblInteractions TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status preclinical

PMIDs:
23680147 25216528 26206558

Sources:
DoCM CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
25753330

Sources:
DTC

Interaction Types & Directionality:

antibody (inhibitory)

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
25753330

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions MyCancerGenomeClinicalTrial

Interaction Types & Directionality:

antibody (inhibitory)

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

antibody (inhibitory)

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
27044931 24685132

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status preclinical

PMIDs:
23680147 30071039 25953157

Sources:
DoCM CIViC PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name AC480

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Clinical Status preclinical

Pathway activation

Variant Effect gain-of-function

PMIDs:
23680147 25398453 25953157

Sources:
DoCM CIViC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24685132 25952648

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)